Novavax (NASDAQ:NVAX) Trading Down 7.3% – Here’s Why

Posted by Geri Gentry on May 30th, 2026

Novavax, Inc. (NASDAQ:NVAX – Get Free Report)’s share price traded down 7.3% during trading on Thursday . The stock traded as low as $10.36 and last traded at $10.2830. 930,816 shares were traded during mid-day trading, a decline of 81% from the average session volume of 4,942,366 shares. The stock had previously closed at $11.09.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. TD Cowen upped their price target on Novavax from $8.00 to $9.00 and gave the company a “hold” rating in a research note on Wednesday, May 6th. HC Wainwright upped their price target on Novavax from $11.00 to $16.00 and gave the company a “buy” rating in a research note on Friday, February 27th. B. Riley Financial reaffirmed a “buy” rating on shares of Novavax in a research note on Thursday, April 9th. Wall Street Zen lowered Novavax from a “hold” rating to a “sell” rating in a research note on Saturday, May 23rd. Finally, Weiss Ratings lowered Novavax from a “hold (c-)” rating to a “sell (d)” rating in a research note on Thursday, May 7th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and four have given a Sell rating to the company’s stock. According to MarketBeat.com, Novavax presently has a consensus rating of “Hold” and an average target price of $12.13.

View Our Latest Analysis on Novavax

Novavax Trading Up 6.3%

The company has a fifty day simple moving average of $8.86 and a two-hundred day simple moving average of $8.36. The company has a market cap of $1.80 billion, a PE ratio of -18.91 and a beta of 2.37.

Novavax (NASDAQ:NVAX – Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.19. Novavax had a negative return on equity of 14.82% and a negative net margin of 14.73%.The company had revenue of $118.90 million for the quarter, compared to the consensus estimate of $79.81 million. During the same quarter in the prior year, the business earned $2.93 EPS. Novavax’s revenue was down 79.0% on a year-over-year basis. On average, research analysts anticipate that Novavax, Inc. will post -0.19 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in NVAX. Shah Capital Management increased its holdings in shares of Novavax by 23.3% in the 4th quarter. Shah Capital Management now owns 14,558,780 shares of the biopharmaceutical company’s stock valued at $97,835,000 after acquiring an additional 2,747,000 shares during the last quarter. State Street Corp increased its holdings in shares of Novavax by 32.3% in the 4th quarter. State Street Corp now owns 9,523,646 shares of the biopharmaceutical company’s stock valued at $63,999,000 after acquiring an additional 2,326,927 shares during the last quarter. UBS Group AG increased its holdings in shares of Novavax by 40.3% in the 4th quarter. UBS Group AG now owns 4,894,284 shares of the biopharmaceutical company’s stock valued at $32,890,000 after acquiring an additional 1,405,981 shares during the last quarter. Allianz Asset Management GmbH increased its holdings in shares of Novavax by 162.6% in the 3rd quarter. Allianz Asset Management GmbH now owns 1,409,734 shares of the biopharmaceutical company’s stock valued at $12,222,000 after acquiring an additional 872,987 shares during the last quarter. Finally, Farallon Capital Management LLC increased its holdings in shares of Novavax by 4,775.0% in the 3rd quarter. Farallon Capital Management LLC now owns 780,000 shares of the biopharmaceutical company’s stock valued at $6,763,000 after acquiring an additional 764,000 shares during the last quarter. Hedge funds and other institutional investors own 53.04% of the company’s stock.

Novavax Company Profile

(Get Free Report)

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.